Cheplapharm to take over 20 medicines and three sites from Sanofi
Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm.
Drug Development
FDA reduces monitoring time for Amgen’s Imdelltra infusions
Exegenesis Bio and Modalis sign research deal for Duchenne therapy
ABEC to expand global manufacturing network with new Wilson facility
Solstice Oncology secures $225m to drive porustobart’s development for cancer
TwoStep Therapeutics raises $62.5m in funding to advance TS-104
Gilead launches research facility in US for new medicine development
FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia
